GLUCOBIOME

Microbiome, metabolic syndrome, diabetes, cardiovascular disease, next generation probiotics
Research Area Nutrition & Metabolism

Glucoregulators of the intestinal microbiome to treat and prevent cardio-metabolic conditions – GLUCOBIOME. Project Ref: PDC2021-121659-I00 funded by MCIN/AEI/ 10.13039/501100011033 and the European Union NextGenerationEU/PRTR. 2021-23. Principal Investigator of CSIC: Prof. Yolanda Sanz

GLUCOBIOME proposes to advance the technological maturity of an innovative biotherapeutic product, based on a human intestinal bacterium, for the treatment and prevention of pathologies associated with alterations in glucose metabolism (metabolic syndrome, type 2 diabetes and cardiovascular diseases). It is a bacterium that acts as a glucoregulator, improving the functioning of the GLP-1 system through endocrine and paracrine routes and showing great specificity of action.

Objectives

  • Evaluate the safety of the patented bacterium through in silico and in vitro models
  • Optimize the growth and scale-up of the production of the bacterium and its bioactive components, ensuring the feasibility of its commercialization.
  • Evaluate the tolerability and safety through toxicological studies.
  • Implement a roadmap for transference and future commercialization of the results

Strategy

  • Demonstration of the safety using different experimental approaches and optimisation and scale-up of the production of the bacteria and their bioactive components.
  • Transfer and exploitation to move towards commercialisation in the food, biotechnology and pharmaceutical fields.

Impact

  • Improving quality of life of patients and at-risk subjects of metabolic syndrome, type 2 diabetes and cardiovascular disease